Dashboard
Manage Tickers

IBRX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jefferies-maintains-buy-on-immunitybio-raises-price-target-to-9
Jefferies Maintains Buy on ImmunityBio, Ra...
12/12/2025 18:59:15

Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $8 to $9.

immunitybio-moves-closer-to-eu-approval-for-bladder-cancer-therapy
ImmunityBio Moves Closer To EU Approval Fo...
12/12/2025 17:00:36

EMA recommends conditional authorization for ImmunityBio's Anktiva with BCG after a 71% complete response rate in BCG-unres...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
12/12/2025 12:45:17

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybios-cancer-therapy-clears-major-eu-hurdle-opening-door-to-earlier-access-for-thousands-of-patients
ImmunityBio's Cancer Therapy Clears Major ...
12/12/2025 11:11:52

ImmunityBio ((IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granti...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
12/11/2025 12:39:56

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

micron-endeavour-silver-first-majestic-silver-applied-digital-and-other-big-stocks-moving-higher-on-friday
Micron, Endeavour Silver, First Majestic S...
11/28/2025 16:19:28

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
11/13/2025 18:26:19

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
11/05/2025 14:00:37

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-q3-eps-007-beats-010-estimate-sales-32061m-beat-31880m-estimate
ImmunityBio Q3 EPS $(0.07) Beats $(0.10) E...
11/05/2025 06:48:15

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) b...

hc-wainwright--co-reiterates-buy-on-immunitybio-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Immu...
09/10/2025 10:57:59

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $8 price t...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
09/08/2025 14:11:25

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-announces-paradigm-changing-findings-from-phase-2-quilt-3055-study-showing-anktiva-reverses-lymphopenia-in-patients-with-checkpoint-inhibitor-resistant-advanced-nsclc-with-reversal-resulting-in-significant-prolonged-mos
ImmunityBio Announces Paradigm Changing Fi...
09/08/2025 12:35:37

Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lo...

whats-going-on-with-immunitybio-shares-tuesday
What's Going On With ImmunityBio Shares Tu...
08/26/2025 16:33:41

ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
08/26/2025 16:26:10

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybios-chemotherapy-free-combo-shows-100-disease-control-in-early-glioblastoma-trial-plans-phase-2
ImmunityBio's Chemotherapy-Free Combo Show...
08/26/2025 12:34:48

First chemotherapy-free trial combining ANKTIVA, an IL-15 agonist, natural killer (NK) cell therapy, and Optune immune-stimulat...

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
08/19/2025 14:47:18

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-opens-new-phase-2-study-to-assess-bioshield-platform-anchored-by-anktiva-in-long-covid-patients
ImmunityBio Opens New Phase 2 Study To Ass...
08/19/2025 12:34:59

d-boral-capital-maintains-buy-on-immunitybio-maintains-24-price-target
D. Boral Capital Maintains Buy on Immunity...
08/14/2025 12:35:13

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.

immunitybio-announces-early-quilt-106-phase-i-data-showing-complete-responses-in-waldenstrom-macroglobulinemia-patients-treated-with-cd19-car-nk-therapy
ImmunityBio Announces Early QUILT-106 Phas...
08/13/2025 12:36:19

Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of ...

immunitybios-anktiva-now-available-at-houston-va-offering-new-bladder-cancer-treatment-for-veterans
ImmunityBio's ANKTIVA Now Available At Hou...
08/11/2025 12:33:56

ImmunityBio, Inc. ((IBRX), a leading immunotherapy company, today announced the Michael E. DeBakey Department of Veterans Affai...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION